(19)
(11) EP 3 994 169 A1

(12)

(43) Date of publication:
11.05.2022 Bulletin 2022/19

(21) Application number: 20734407.8

(22) Date of filing: 29.06.2020
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 38/20(2006.01)
 A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/505; C07K 16/2815; C07K 2319/00; A61P 35/00; C07K 14/55; A61K 38/00
(86) International application number:
PCT/EP2020/068186
(87) International publication number:
WO 2021/001289 (07.01.2021 Gazette 2021/01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 02.07.2019 EP 19183829

(71) Applicant: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • FREIMOSER-GRUNDSCHOBER, Anne
    8952 Schlieren (CH)
  • KLEIN, Christian
    8952 Schlieren (CH)
  • UMAÑA, Pablo
    8952 Schlieren (CH)
  • WALDHAUER, Inja
    8952 Schlieren (CH)

(74) Representative: Brodbeck, Michel 
F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)

   


(54) IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 AND AN ANTI-CD8 ANTIBODY